van Eeden Ronwyn, Rapoport Bernardo L
The Medical Oncology Centre, Rosebank, Johannesburg, South Africa.
Curr Opin Support Palliat Care. 2016 Jun;10(2):189-94. doi: 10.1097/SPC.0000000000000209.
Anaemia is a common problem in patients with solid tumors and haematological malignancies. Certain cancer therapies also contribute to anaemia. This article reviews the pathophysiology of cancer-related anaemia, investigation of a cancer patient with anaemia as well as how anaemia impacts patients in terms of quality of life, disease-related outcomes and treatment choices.
Different treatments for anaemia include transfusions, erythropoiesis-stimulating agents (ESA) and iron therapy. Within this context, we review the advantages and disadvantages concerning anaemia management in cancer patients as well as the risk-benefit ratio of different treatment choices, particularly the increased risk of thromboembolic events of ESAs and concern around mortality and effect on tumor growth.
This review is aimed at guiding treating physicians to make the best evidence-based treatment choices according to the product label and according to current guidelines for patients with cancer-related anaemia.
贫血是实体瘤和血液系统恶性肿瘤患者的常见问题。某些癌症治疗也会导致贫血。本文综述了癌症相关性贫血的病理生理学、贫血癌症患者的检查，以及贫血对患者生活质量、疾病相关结局和治疗选择的影响。
贫血的不同治疗方法包括输血、促红细胞生成素（ESA）和铁剂治疗。在此背景下，我们综述了癌症患者贫血管理的利弊以及不同治疗选择的风险效益比，特别是ESA血栓栓塞事件风险增加以及对死亡率和肿瘤生长影响的担忧。
本综述旨在指导治疗医师根据产品标签和当前癌症相关性贫血患者指南做出最佳循证治疗选择。
